MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma

Yong Qing Tong, Bei Liu, Hong Yun Zheng, Jian Gu, Hang Liu, Feng Li, Bi Hua Tan, Melanie Hartman, Chunhua Song, Yan Li

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

MicroRNA-215 (miR-215) promotes tumor growth in various human malignancies. However, its role has not yet been determined in human glioma. Here, we found that levels of miR-215 were higher in glioma tissues than in corresponding non-neoplastic brain tissue. High miR-215 expression was correlated with higher World Health Organization (WHO) grades and shorter overall survival. Multivariate and univariate analysis indicated that miR-215 expression was an independent prognostic factor. We also found that TGF-beta1, phosphorylated beta-catenin, alpha-SMA, and fibronectin were increased in glioma tissues. Additionally, CTNNBIP1, a direct target of miR-215, was decreased in glioma compared to adjacent normal tissue. These data indicate that miR-215 activates Wnt/ß-catenin signaling by increasing ß-catenin phosphorylation, a-SMA expression, and fibronectin expression. It promotes TGF-ß1- induced oncogenesis by suppressing CTNNBIP1 in glioma. In summary, miR-215 is overexpressed in human glioma, is involved in TGF-ß1-induced oncogenesis, and can be used as a marker of poor prognosis in glioma patients.

Original languageEnglish (US)
Pages (from-to)25024-25033
Number of pages10
JournalOncotarget
Volume6
Issue number28
DOIs
StatePublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma'. Together they form a unique fingerprint.

  • Cite this

    Tong, Y. Q., Liu, B., Zheng, H. Y., Gu, J., Liu, H., Li, F., Tan, B. H., Hartman, M., Song, C., & Li, Y. (2015). MiR-215, an activator of the CTNNBIP1/ß-catenin pathway, is a marker of poor prognosis in human glioma. Oncotarget, 6(28), 25024-25033. https://doi.org/10.18632/oncotarget.4622